MiNK Therapeutics, Inc. (INKT)
Nasdaq: INKT · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2021
Who owns MiNK Therapeutics, Inc.
As filed with the SECHolders of 5% or more
0
No Schedule 13D or 13G naming this company is on file.
Directors and officers
9
report now, of 14 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 0 named at left.
Holders of 5% or moreshare of the class, as filed
No holder of 5% or more is on file in a Schedule 13D or 13G naming this company.
What INKT reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 31, 2026.
Insider tradesForm 4
9sales
0purchases
0sales on a scheduled plan
2people selling
$100,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 14, 2025 to Oct 14, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 14, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 15 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Buell Jennifer | Chief Executive Officer | 1 | $100,000 | 0 | 0 | $0 |
| Ryan Barbara | director | 8 | $0 | 0 | 0 | $0 |